A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells

Clinical Cancer Research

Volumn 16, Issue 15, 2010, Pages 3964-3975

  Mizutani, Tatsuaki ^a   Kondo, Takeshi ^a   Darmanin, Stephanie ^a   Tsuda, Masumi ^a   Tanaka, Shinya ^a   Tobiume, Minoru ^b   Asaka, Masahiro ^a   Ohba, Yusuke ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CHIMERIC PROTEIN; CRK LIKE PROTEIN; CYAN FLUORESCENT PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PROTEIN SH2; PROTEIN VENUS; TYROSINE; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN;

ADULT; AGED; ARTICLE; BIOSENSOR; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MALE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; BIOSENSING TECHNIQUES; BLOTTING, WESTERN; CELL SEPARATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LUMINESCENT AGENTS; NUCLEAR PROTEINS; PHOSPHORYLATION; PIPERAZINES; PYRIMIDINES; SENSITIVITY AND SPECIFICITY;

EID: 77955099778     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0548     Document Type: Article

References (49)

1. Sawyers C. Targeted cancer therapy. Nature 2004;432:294-7.
2. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988;319:990-8.
3. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984;36:93-9. (Pubitemid 14155374)
4. Heisterkamp N, Groffen J, Stephenson JR, et al. Chromosomal localization of human cellular homologues of two viral oncogenes. Nature 1982;299:747-9.
5. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
6. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008;112:4808-17.
7. Druker BJ, O'Brien SG, Cortes J, Radich J. Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program) 2002;2002:111-35.
8. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7:345-56.
9. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006;108:1478-84.
10. Feller SM. Crk family adaptors-signalling complex formation and biological roles. Oncogene 2001;20:6348-71.
11. Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 1994;84:2912-8. (Pubitemid 24328078)
12. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994;269:22925-8.
13. ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. Blood 1994;84:1731-6.
14. White D, Saunders V, Lyons AB, et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005;106:2520-6.
15. Yamada T, Tsuda M, Ohba Y, Kawaguchi H, Totsuka Y, Shindoh M. PTHrP promotes malignancy of human oral cancer cell downstream of the EGFR signaling. Biochem Biophys Res Commun 2008;368:575-81.
16. Ohba Y, Kurokawa K, Matsuda M. Mechanism of the spatio-temporal regulation of Ras and Rap1. EMBO J 2003;22:859-69.
17. Hamilton A, Elrick L,Myssina S, et al.BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia 2006;20:1035-9.
18. Altman DG, Bland JM. The Normal-Distribution. Br Med J 1995;310:298.
19. Kurokawa K, Mochizuki N, Ohba Y, Mizuno H, Miyawaki A, Matsuda M. A pair of fluorescent resonance energy transfer-based probes for tyrosine phosphorylation of the CrkII adaptor protein in vivo. J Biol Chem 2001;276:31305-10.
20. Nagai T, Ibata K, Park ES, Kubota M, Mikoshiba K, Miyawaki A. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat Biotechnol 2002;20:87-90. (Pubitemid 34044921)
21. Yoshizaki H, Ohba Y, Kurokawa K, et al. Activity of Rho-family GTPases during cell division as visualized with FRET-based probes. J Cell Biol 2003;162:223-32.
22. Ting AY, Kain KH, Klemke RL, Tsien RY. Genetically encoded fluorescent reporters of protein tyrosine kinase activities in living cells. Proc Natl Acad Sci U S A 2001;98:15003-8.
23. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.
24. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
25. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-41.
26. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-5.
27. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009;27:469-71.
28. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
29. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-56.
30. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657-67.
31. Keating A, Wang XH, Laraya P. Variable transcription of BCR-ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia. Blood 1994;83:1744-9. (Pubitemid 24107895)
32. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40.
33. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52.
34. Tkachuk DC, Westbrook CA, Andreeff M, et al. Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization. Science 1990;250:559-62.
35. Preudhomme C, Revillion F, Merlat A, et al. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a "real time" quantitative RT-PCR assay. Leukemia 1999;13:957-64.
36. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon α plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32.
37. Weerkamp F, Dekking E, Ng YY, et al. Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients. Leukemia 2009;23:1106-17.
38. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
39. White D, Saunders V, Grigg A, et al. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 2007;25:4445-51.
40. Hamilton A, Alhashimi F, Myssina S, Jorgensen HG, Holyoake TL. Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells. Exp Hematol 2009;37:395-401.
41. Desplat V, Lagarde V, Belloc F, et al. Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells. Cytometry A 2004;62:35-45. (Pubitemid 39473451)
42. Schultheis B, Szydlo R, Mahon FX, Apperley JF, Melo JV. Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. Blood 2005;105:4893-4.
43. Patel H, Marley SB, Gordon MY. Detection in primary chronic myeloid leukaemia cells of p210BCR-ABL1 in complexes with adaptor proteins CBL, CRKL, GRB2. Genes Chromosomes Cancer 2006;45:1121-9.
44. Azam M, Nardi V, Shakespeare WC, et al. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci U S A 2006;103:9244-9.
45. Zhang J, Adrian FJ, Jahnke W, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010;463:501-6.
46. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7. (Pubitemid 27298715)
47. Savona M, Talpaz M. Getting to the stemof chronic myeloid leukaemia. Nat Rev Cancer 2008;8:341-50.
48. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84.
49. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-9.